Author/Editor | Nalli, C; Andreoli, L; Motta, M; Norman, GL; Shums, Z; Binder, WL; Nuzzo, M; Frassi, M; Lojacono, A; Avčin, T | |
Title | La fine specificita degli anticorpi anti-beta2 glicoproteina I nelle malattie autoimmuni sistemiche e prevalentemente diretta verso il dominio 1 | |
Translated title | Fine specificity of anti-beta2glycoprotein I antibodies in systemic autoimmune diseases is mostly directed against domain 1 | |
Type | članek | |
Source | Reumatismo | |
Vol. and No. | Letnik 63, št. 2 | |
Publication year | 2011 | |
Volume | str. 91-6 | |
Language | ita | |
Abstract | Objective: Anti-beta2 GPI are a formal laboratory criterion for the antiphospholipid syndrome (APS). They were demonstrated to be a risk factor for thrombosis and fetal losses but can also be detected in patients with systemic autoimmune disease (SAD), in healthy adults individuals and pre-school children. It has been suggested that different subpopulations of anti-beta2GPI may carry different pathogenetic potential: autoantibodies against Domain1 seem to be associated with thrombosis; autoantibodies against Domain4/5 have been identified in patients with non-thrombotic conditions. Methods: We studied 48 patients with SAD (32 systemic lupus erythematosus, 16 undifferentiated connettive tissue disease), 64 patients with APS, 57 one-year-old healthy children born to mother with SAD, 33 children with atopic dermatitis. All subjects were IgG anti-beta2 GPI positive. The specificity of anti-beta2 GPI was investigated using ELISA research products containing recombinant beta2 GPI D1 and D4/5 antigens. Cut-off values are calculated as 95th percentile on 100 NHD. IgG anti-beta2 GPI were tested at a validated home-made ELISA routinely performed in our laboratory. No thrombotic events were recordered in patients with SAD and in both groups of children. Results: Patients with SAD and APS showed prevalent reactivity for D1 while children in both groups preferentially recognize D4/5. Conclusions: IgG anti-beta2 GPI against D1 seem to cluster in patients with systemic autoimmune conditions. Their pathogenic potential in determine APS manifestations may be mitigated by adequate prophylaxis. | |
Descriptors | ANTIPHOSPHOLIPID SYNDROME ANTIBODIES, ANTIPHOSPHOLIPID THROMBOSIS AUTOANTIBODIES IGG LUPUS ERYTHEMATOSUS, SYSTEMIC DERMATITIS, ATOPIC ENZYME-LINKED IMMUNOSORBENT ASSAY GLYCOPROTEINS |